Click here to watch the video version of this podcast.
Podcast Question Timestamps from Paul Karpecki:
1:14: Walk us through your personal background, where you grew up, your education, if it’s relevant to what you do now professional path into eye care, some of the steps along the way?
5:26: Tell me a little bit about the company itself.
9:00: Can you point to some things for perhaps someone who’s getting ready to launch a product in terms of what made this so successful, especially in the light of the fact that it’s a first time drug in the category?
15:35: You just mentioned that you’re finishing trials in stage one patients. what’s the plan and pattern now for Oxervate continued success? Is it more education? Is it the next phase of clinical trials? Is it other avenues? What are you thinking that can keep this success going?
21:40: For our listeners who may be looking to maybe reach a position like senior vice president global head of medical clinical affairs, what would be your advice to them? Especially in light of the fact that you took a path that makes a lot of sense, in hindsight, but maybe not everybody goes from pharmacy to this type of a role utilizing their skills. Is it just continuing to learn? Is it also your desire and drive? What can you say, are some of the keys to reaching this pivotal spot?
Dompé, a family-owned global biopharmaceutical company with roots that date back over 150 years, built its legacy by following two principles: take calculated risks, and focus on need rather than precedent.
Georgea Pasedis, PharmD, RPh, Dompé’s Senior Vice President and Global Head of Medical Affairs, moved into her current role by following similar principles. After earning her PharmD and practicing at the renowned Mass Eye and Ear in Boston, Dr. Pasedis determined she could make a broader impact by transitioning to industry.
In her medical affairs role, Dr. Pasedis discusses the science behind Dompé’s products with physicians worldwide. That education includes intel on rhNGF (recombinant human Nerve Growth Factor), the protein that forms the basis for Oxervate (cenegermin-bkbj) the first FDA-approved treatment for neurotrophic keratitis (NK).
With podcast host Paul Karpecki, OD, FAAO, Dr. Pasedis discusses the mechanism of action behind Oxervate and how it helps both early- and late-stage NK patients.
She also discusses how Dompé has remained a successful family-owned business for multiple generations. Its U.S. subsidiary, launched in 2018 in record time, serves as an example of Dompé’s approach to science, to education, and to improving eye health for patients worldwide.
Listen to the podcast today to discover:
• How Dr. Pasedis’ nonlinear career path led her to Dompé.
• How Dompé harnesses innovation differently as a family-owned business.
• How Dompe built out its U.S. launch in only three months.
• Why physician education is so important when it comes to diagnosing and treating NK.
• Dompe’s long-term plan for Oxervate, including in both early- and late-stage NK patients.
• Advice for other professionals considering a transition from the clinic to industry.
Please also see the Prescribing Information for complete information on the approved label indication and Important Safety Information (bit.ly/OXERVATE_Prescribing_Information)
The intent of this material is to provide non-promotional corporate awareness for Dompé R&D platforms
Aloe L, Rocco ML, Bianchi P, Manni L. Nerve growth factor: from the early discoveries to the potential clinical use. J Transl Med. 2012;10:239. Published 2012 Nov 29.
Bonini S, Lambiase A, Rama P, et al; Phase II Randomized, Double-Masked, Vehicle-Controlled Trial of Recombinant Human Nerve Growth Factor for Neurotrophic Keratitis. Ophthalmology. 2018 Sep;125(9):1332-1343.
Pflugfelder SC, Massaro-Giordano M, Perez VL, et al. Topical Recombinant Human Nerve Growth Factor (Cenegermin) for Neurotrophic Keratopathy: A Multicenter Randomized Vehicle-Controlled Pivotal Trial. Ophthalmology. 2020;127(1):14-26
Data on File